Evidence map›Paper›PMID 42422843›Full record

ArticleFrontiers in medicine2026

Case Report: Rapid progression to end-stage renal disease within 3 years in tuberous sclerosis complex challenging conventional risk stratification.

Rushuang Yang, Xing Zheng, Ting Wang, Yanling Zhang

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rushuang YangDepartment of Nephrology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.
Xing ZhengDepartment of Nephrology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.
Ting WangDepartment of Nephrology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.
Yanling ZhangDepartment of Nephrology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder, with renal involvement typically presenting as angiomyolipomas (AML) and cysts. The progression to end-stage renal disease (ESRD) occurs in about 3.1% of cases. Current guidelines use AML size (>3 cm) as the threshold for initiating mTOR inhibitors, with less focus on rapidly progressing disease. This report describes a 28-year-old female with TSC whose renal function rapidly progressed from advanced CKD (stage G4A3) to anuria and ESRD within 3 years. She presented with significant proteinuria (3+, 5.94 g/24 h) and hematuria (3+) during pregnancy, but imaging showed no large tumors. Due to financial constraints, treatment was interrupted. Over approximately 30 months, her bilateral kidneys were replaced by diffuse AML, resulting in renal failure. This case challenges the traditional view of slow kidney progression in TSC and underscores the importance of early detection of proteinuria and hematuria as key warning signs. We recommend a multidisciplinary team (MDT) approach for high-risk patients, such as women of childbearing age, with dynamic monitoring of renal function and early proactive treatment to delay ESRD progression.

Indexed as

angiomyolipomacase reportend-stage renal diseasemultidisciplinary teamtuberous sclerosis complex

Identifiers

PMID42422843
PMCPMC13341703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.